Franco Vizeacoumar

Dr. Franco Vizeacoumar is a Professor of Experimental Oncology at the University of Saskatchewan’s Department of Oncology, with an associate membership in the Department of Pathology. His lab focuses on developing genotype-directed cancer therapies using synthetic lethality principles, aiming to exploit genetic vulnerabilities in tumors. His research integrates genetic interaction mapping, drug screening, and molecular biology to identify novel therapeutic targets.

Education details are not explicitly stated, but his academic roles and publications suggest advanced training in molecular biology and oncology. His lab’s work emphasizes personalized medicine, targeting cancer cells’ genetic dependencies to overcome heterogeneity and improve treatment efficacy.

Key research areas include synthetic lethality networks, Eph receptor biology, and drug repurposing for aggressive cancers like neuroendocrine prostate cancer and endometrial cancer. Collaborations with institutions like the Saskatchewan Cancer Agency and interdisciplinary teams (e.g., Freywald Lab) enhance translational research efforts.

Students and trainees in his lab have received numerous awards, including CIHR scholarships, CoMGRAD fellowships, and MITACS grants, highlighting the lab’s high academic and scientific impact. Notable achievements include identifying PLK1 vulnerabilities and developing bispecific antibodies targeting EGFR/EPHA2.

His lab’s long-term vision is to build comprehensive genetic interactomes to guide precision oncology, integrating proteomics, genomics, and synthetic lethality screens for actionable insights.